ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

Early Studies Reveal Efficacy, Safety Concerns With Vadastuximab Talirine in Patients With Acute Myeloid...

Early studies of vadastuximab talirine (33A) in patients with acute myeloid leukemia (AML) have shown preliminary efficacy, whether the drug has been used as...

Phase I Study Shows Venetoclax Active in Patients With Relapsed/Refractory Myeloma

The B-cell lymphoma/leukemia-2 (BCL-2) inhibitor venetoclax may be a new option for patients with heavily treated multiple myeloma (MM), according to results from an...

Newly Approved Drugs: How to Use Them in Practice

In 2016, the U.S. Food and Drug Administration (FDA) approved several new therapies for the treatment of hematologic disorders, marking several “firsts” for hematology,...

BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic Mastocytosis

BLU-285, an oral inhibitor of KIT D816V, is well tolerated and could alleviate symptom burden for patients with advanced systemic mastocytosis (SM), according to...

Double Hematopoietic Cell Transplantation Extends Progression-Free Survival Over Single Transplant in Myeloma Patients

Following bortezomib-based induction therapy, patients with newly diagnosed multiple myeloma (MM) who received double autologous hematopoietic cell transplantation (AHCT) had longer progression-free survival (PFS)...

Does the Addition of ATLG Improve Outcomes After Allogeneic Transplantation?

Previous studies have suggested that adding anti-T lymphocyte globulin (ATLG) to the treatment regimen for patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) could reduce...

For Patients on Dialysis With Venous Thromboembolism, Low-Molecular-Weight Heparin May Be a Better Option...

Low-molecular-weight heparins (LMWHs) are not traditionally used to treat venous thromboembolism (VTE) in patients on dialysis, but results from a study presented at the...

Clonal Hematopoiesis Predicts Patients Likely to Develop Therapy-Related Myeloid Neoplasms

Screening for clonal hematopoiesis at the time of cancer diagnosis could help identify patients with an increased risk of developing secondary, therapy-related myeloid neoplasms...

Subcutaneous Delivery of Daratumumab Is Safe, Effective in Multiple Myeloma

While daratumumab was approved by the U.S. Food and Drug Administration (FDA) as an intravenous (IV) infusion for the treatment of multiple myeloma (MM),...

Results from Phase III SWOG Trial: 7+3 Still the Standard of Care for Patients...

Remission induction with 7+3 chemotherapy (cytarabine + daunorubicin) should remain the standard of care for younger patients with acute myeloid leukemia (AML), according to...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.